A5103231025- Antifungal resistance and susceptibility
- Immunotherapy and Immune Responses
- Neutropenia and Cancer Infections
- Fungal Infections and Studies
- Cancer Immunotherapy and Biomarkers
- Neuroblastoma Research and Treatments
- CAR-T cell therapy research
- Childhood Cancer Survivors' Quality of Life
- Cancer therapeutics and mechanisms
- Soft tissue tumor case studies
- Cancer Diagnosis and Treatment
- Pleural and Pulmonary Diseases
- Oral and Maxillofacial Pathology
- Cancer Genomics and Diagnostics
- Sarcoma Diagnosis and Treatment
- Herbal Medicine Research Studies
- Education, Psychology, and Social Research
- Pneumocystis jirovecii pneumonia detection and treatment
- Pancreatic and Hepatic Oncology Research
- Acute Lymphoblastic Leukemia research
- Ocular Oncology and Treatments
- Fungal Plant Pathogen Control
- HIV-related health complications and treatments
- HIV/AIDS drug development and treatment
- Multiple and Secondary Primary Cancers
Masaryk University
2017-2020
University Hospital Brno
2006-2020
Infantile myofibromatosis belongs to a family of soft tissue tumors. The majority these tumors have benign behavior but resistant and malignant courses are known, namely in with visceral involvement. standard care is surgical resection. Observations suggest that low dose chemotherapy beneficial. treatment or relapsed patients multifocal disease remains challenging. Patients harbor an actionable mutation the kinase domain potential subjects for targeted tyrosine inhibitor therapy. An infant...
To outline an outpatient-based treatment for children with relapsed solid tumors, who already have been extensively pretreated, we defined a 4-drug protocol named COMBAT (combined oral maintenance biodifferentiating and antiangiogenic therapy). Using this protocol, performed pilot study to determine its feasibility in and/or high-risk pediatric tumors.22 received the protocol. Treatment consisted of daily celecoxib administration along 13-cisretinoic acid (2 weeks on / 2 off) cycles...
Infantile myofibromatosis represents one of the most common proliferative fibrous tumors infancy and childhood. More effective treatment is needed for drug-resistant patients, targeted therapy using specific protein kinase inhibitors could be a promising strategy. To date, several studies have confirmed connection between p.R561C mutation in gene encoding platelet-derived growth factor receptor beta (PDGFR-beta) development infantile myofibromatosis. This study aimed to analyze...
Despite efforts to develop novel treatment strategies, refractory and relapsing sarcoma high-risk neuroblastoma continue have poor prognoses limited overall survival. Monocyte-derived dendritic cell (DC)-based anti-cancer immunotherapy represents a promising modality in these neoplasias. A DC-based vaccine was evaluated for safety an academic phase I/II clinical trial children, adolescent young adults with progressive, recurrent or primarily metastatic tumors, mainly sarcomas neuroblastomas....
Monocyte-derived dendritic cell (DC)-based vaccines loaded with tumor self-antigens represent a novel approach in anticancer therapy. We evaluated DC-based immunotherapy (ITx) an academic Phase I/II clinical trial for children, adolescent, and young adults progressive, recurrent, or primarily metastatic high-risk tumors. The primary endpoint was safety of intradermal administration manufactured DCs. Here, we focused on relapsing sarcoma subgroup representing major diagnosis DC trial. As part...
Východiska: Maff ucciho syndrom je vzácné kongenitální nehereditární onemocnění charakterizované přítomností mnohočetných hemangiomů a enchondromů s tendencí k malignímu zvratu.Kauzální terapie neexistuje léčba zaměřena na řešení komplikací.Stanovení vhodného postupu komplikované často nutná multioborová spolupráce v péči o tyto
Our study aimed to evaluate incidence and mortality trends for childhood adolescent cancers in the period 1994-2016 Czech Republic.Data on cancers, which are recorded National Cancer Registry, were validated using a clinical database of cancer patients combined with data from Register Hospitalised Patients death certificates. These used establish incidence. Data certificates long-term mortality. Incidence assessed by average annual percentage change.The age-standardised trend (i.e. those...
Sunitinib patří do skupiny protinádorových léčiv, jejichž mechanismus účinku je založen na inhibici řady tyrozinkinázových receptorů (RKTs), které přispívají k růstu nádoru, patologické angiogenezi a metastatické progresi nádorového onemocnění.Především se jedná o pro růstový faktor z destiček (PDGFR -α PDGFR -β), vaskulární endoteliální (VEGFR-1, VEGFR-2 VEGFR-3), faktoru kmenových buněk (Kit), Fms podobné tyrozinkinázy 3 (Flt3, -like tyrosine kinase-3), kolonie stimulujícího (CSF-1R)...